Philips

Philips (Koninklijke Philips N.V.) was founded in Eindhoven, the Netherlands, in 1891 by Gerard Philips and his father Frederik Philips. The company is publicly traded on Euronext Amsterdam under the ticker PHIA, and its American Depositary Shares trade on the New York Stock Exchange under PHG. Over its long history Philips transformed from a light-bulb manufacturer into one of the largest health technology companies in the world, having divested its lighting division (spun off as Signify in 2018) and its consumer electronics and domestic appliances businesses in order to focus exclusively on health technology.

Philips employs tens of thousands of people globally across its health technology businesses, with headquarters remaining in Amsterdam.

Philips operates across three core health technology domains: diagnostic imaging (MRI systems, CT scanners, ultrasound, and X-ray), image-guided therapy (interventional systems used in cardiology and radiology procedures), and connected care (patient monitoring systems, telehealth, and sleep and respiratory care devices). The company sells primarily to hospitals, health systems, and clinics, with enterprise-level capital equipment contracts and long-cycle service agreements forming the backbone of its revenue model. Its sleep and respiratory care segment markets devices such as the CPAP and BiPAP product lines directly to patients and through home-care providers.

Philips's flagship diagnostic imaging portfolio includes MRI systems sold under the Ingenia and Elition brand names, as well as CT systems and ultrasound devices. The image-guided therapy business centers on the Azurion platform, an interventional X-ray system used in cardiac catheterization labs. In connected care, the IntelliVue patient monitoring line is widely deployed in intensive care units. The sleep and respiratory care segment produces the DreamStation CPAP devices — a line that became the subject of a major regulatory and recall crisis starting in 2021, when Philips recalled millions of sleep and respiratory care devices globally due to potential degradation of sound-abatement foam that could release harmful particles or gases. That recall, overseen by the U.S. FDA among other regulators, resulted in substantial financial charges, regulatory consent decrees, and litigation settlements that continued to affect the company through 2024.

In diagnostic imaging Philips competes directly with Siemens Healthineers and GE HealthCare, with the three companies collectively dominating the global market for large-bore MRI and CT systems. In patient monitoring the primary competitors are Philips's own historical rivals GE HealthCare and Masimo. The Respironics recall significantly damaged Philips's position in the sleep therapy device market, where ResMed is the dominant player and benefited substantially from Philips's supply disruptions.

Philips maintains a research and development presence in Israel, historically centered in the area around Tel Aviv through its Philips Healthcare innovation activities. Israel has been a site for healthcare technology R&D for Philips, though detailed current headcount figures are not publicly confirmed in my training data.